Advertisement

Interaction of Ketamine and Cannabis in Bipolar Disorder

  • Helge Hasselmann
    Correspondence
    Address correspondence to: Helge Hasselmann, M.Sc., Clinic for Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12203, Germany.
    Affiliations
    Clinic for Psychiatry and Psychotherapy and NeuroCure Clinical Research Center, Charité Universitätsmedizin Berlin, Berlin, Germany
    Search for articles by this author
      I read with great interest a recent correspondence by McInnes et al. (
      • McInnes A.L.
      • James-Myers M.B.
      • Turner M.S.
      Possible affective switch associated with intravenous ketamine treatment in a patient with bipolar I disorder.
      ) regarding a possible switch from depression to mania/mixed state in a woman with bipolar disorder type I. Briefly, the authors found that the 44-year-old patient treated with various outpatient medications (lithium 600 mg, aripiprazole 10 mg, modafinil 100 mg, clonazepam 1 mg, and zolpidem 10 mg, and lorazepam .5 mg on demand) developed an affective switch following a single 40-minute continuous intravenous infusion of ketamine .5 mg/kg.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McInnes A.L.
        • James-Myers M.B.
        • Turner M.S.
        Possible affective switch associated with intravenous ketamine treatment in a patient with bipolar I disorder.
        Biol Psychiatry. 2016; 79: e71-e72
        • Aan Het Rot M.
        • Zarate Jr, C.A.
        • Charney D.S.
        • Mathew S.J.
        Ketamine for depression: Where do we go from here?.
        Biol Psychiatry. 2012; 72: 537-547
        • Hasselmann H.W.
        Ketamine as antidepressant? Current state and future perspectives.
        Curr Neuropharmacol. 2013; 230: 291-298
        • Da Frota Ribeiro C.M.
        • Sanacora G.
        • Hoffman R.
        • Ostroff R.
        The use of ketamine for the treatment of depression in the context of psychotic symptoms.
        Biol Psychiatry. 2016; 79: e65-e66
        • Niciu M.J.
        • Luckenbaugh D.A.
        • Ionescu D.F.
        • Mathews D.C.
        • Richards E.M.
        • Zarate C.A.
        Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.
        Biol Psychiatry. 2013; 74: e23-e24
        • Chen J.T.
        • Chen R.M.
        Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression.
        Expert Opin Drug Metab Toxicol. 2010; 6: 273-281
        • Stout S.M.
        • Cimino N.M.
        Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review.
        Drug Metab Rev. 2014; 46: 86-95
        • Thomas H.
        Psychiatric symptoms in cannabis users.
        Br J Psychiatry. 1993; 163: 141-149
        • Thomas H.
        A community survey of adverse effects of cannabis use.
        Drug Alcohol Depend. 1996; 42: 201-207
        • Gibbs M.
        • Winsper C.
        • Marwaha S.
        • Gilbert E.
        • Broome M.
        • Singh S.P.
        Cannabis use and mania symptoms: A systematic review and meta-analysis.
        J Affect Disord. 2015; 171: 39-47
        • Goldberg J.F.
        • Perlis R.H.
        • Ghaemi S.N.
        • Calabrese J.R.
        • Bowden C.L.
        • Wisniewski S.
        • et al.
        Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: Findings from the STEP-BD.
        Am J Psychiatry. 2007; 164: 1348-1355

      Linked Article

      • Possible Affective Switch Associated With Intravenous Ketamine Treatment in a Patient With Bipolar I Disorder
        Biological PsychiatryVol. 79Issue 9
        • Preview
          A collaborative team of doctors and nurses from the Departments of Psychiatry and Anesthesiology at Kaiser Permanente started the Ketamine Infusion Therapy Program for treatment of unipolar and bipolar depression in fall 2014. We have treated 40 patients with both diagnoses since inception of the program, and we have observed one possible ketamine-induced case switch from depression to mixed mania among seven patients with bipolar disorder (n = 4 bipolar disorder type II and n = 3 bipolar disorder type I) treated.
        • Full-Text
        • PDF